Clindamycin Palmitate vs Clindamycin In 5 Percent Dextrose — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Lincosamide Antibacterial

Clindamycin Palmitate

Brand: Cleocin Pediatric

First FDA approval: 1986-04-17

Lincosamide Antibacterial

Clindamycin In 5 Percent Dextrose

First FDA approval: 2013-02-07

Lowest NADACAcquisition cost floor across all NDCs

$0.139Per unit

—Per unit

Average NADACAcross all dosage forms and strengths

$0.139Up to $0.139

—

Generic manufacturersActive ANDA holders — FDA Orange Book

77 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$730703Full year

—Full year

Part D claims (CY24)Total fills, all strengths

7K6K beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$98Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

84Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

Active shortageSee drug profile

Generic availableFDA Orange Book

Yes7 manufacturers

NoBrand-only